

## AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claims 1-5 (Canceled).

Claim 6 (Original). A compound selected from the group consisting of  
4-(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-ol,  
(*R*)-1-[4-(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-ol,  
(*S*)-1-[4-(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-ol,  
(*R*)-1-[4-(4-Fluoro-2-methyl-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-ol,  
(*R*)-2-[4-(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethylamine,  
(*R*)-2-[4-(4-Fluoro-2-methyl-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methyl-ethylamine,  
2-[4-(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-ethylamine,  
(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine,  
(4-Fluoro-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine,  
(4-Fluoro-2-methyl-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine, and  
[5-Isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-(2-methyl-1*H*-pyrrolo[2,3-b]pyridin-5-yl)-amine.

Claim 7 (Canceled).

Claim 8 (Previously presented). A pharmaceutical composition comprising one or more of the compounds of Claim 6 and a pharmaceutically acceptable carrier therefor.

Claims 9-20 (Canceled).